Clinical Trial Update: Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial update for MDV3100 (enzalutamide) in castration-resistant prostate cancer previously treated with docetaxel; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• MDV3100 (enzalutamide)

Snippet

Sponsor: Pfizer | Conditions: Castration-Resistant Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2012-10-30